Online Database of Chemicals from Around the World

(R)-[(5R,7S)-5-乙烯基-1-氮杂双环[2.2.2]辛烷-7-基]-(6-甲氧基喹啉-4-基)甲醇
[CAS# 72646-90-3]

供应商
Interbioscreen Ltd. 俄罗斯 询价快递  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
化学品生产商
MP Biomedicals LLC. 美国 询价快递  
+1 (440) 337-1200
info@mpbio.com
化学品生产商
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
Sigma-Aldrich, Inc. 美国 询价快递  
+86 (21) 6141-5566 / 800-819-3336
ordercn@sial.com,
化学品生产商(1992 年起)
ZereneX Molecular Ltd. 英国 询价快递  
+44 (1204) 527-700
sales@zerenex-molecular.com
化学品生产商
基本信息
产品名称 (R)-[(5R,7S)-5-乙烯基-1-氮杂双环[2.2.2]辛烷-7-基]-(6-甲氧基喹啉-4-基)甲醇
英文名 (R)-[(5R,7S)-5-Ethenyl-1-Azabicyclo[2.2.2]Octan-7-Yl]-(6-Methoxyquinolin-4-Yl)Methanol
别名 (R)-(6-Methoxy-4-Quinolyl)-[(2S,5R)-5-Vinylquinuclidin-2-Yl]Methanol; (R)-(6-Methoxy-4-Quinolyl)-[(2S,5R)-5-Vinyl-2-Quinuclidinyl]Methanol
分子结构 CAS 登录号:72646-90-3, (R)-[(5R,7S)-5-乙烯基-1-氮杂双环[2.2.2]辛烷-7-基]-(6-甲氧基喹啉-4-基)甲醇
分子式 C20H24N2O2
分子量 324.42
CAS 登录号 72646-90-3
EINECS 登录号 205-003-2
分子行输入简码 SMILES [C@@H]1(N2C[C@@H](C(C1)CC2)C=C)[C@H](O)C3=CC=NC4=CC=C(OC)C=C34
国际化学标识码 InChI 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14?,19-,20+/m0/s1
国际化学标识检索码 InChIKey LOUPRKONTZGTKE-VOMFEXJBSA-N
物理化学性质
密度 1.2±0.1g/cm3 (计算值)
沸点 495.9±40.0°C at 760 mmHg (计算值)
闪点 253.7±27.3°C (计算值)
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览(R)-[(5R,7S)-5-乙烯基-1-氮杂双环[2.2.2]辛烷-7-基]-(6-甲氧基喹啉-4-基)甲醇市场分析报告总目录
相关产品
(2R,3S,4S,5S,6R)-2-(4-硝基苯...  1-(十八烷基氨基)丙-2-醇  [(3S,8R,9S,10R,13S,14S,17...  N-[4-(4,5-二氢-1H-咪唑-2-基甲基)...  2-[(2,3,5,6-四甲基苯基)甲基]-4,5...  2-[(4-溴-2,3,5,6-四甲基苯基)甲基]...  2-[(2,3,5,6-四甲基-4-硝基苯基)甲基...  5-(呋喃-2-基甲基)-2,2-二甲基-1,3-...  5-(1H-吲哚-3-基甲基)-2,2-二甲基-1...  2,2,2-三氯-1-(4-氯-1H-吡咯-2-基...  1-(4-乙酰基-1H-吡咯-2-基)-2,2,2...  甲基4-[5-[5-(4,5-二羟基-6-甲基四氢...  4-[(2R,4aR,5R,6R,7aS)-6-羟...  (-)-Isostegnane  (4Z)-N-(4-乙氧基苯基)-4-[[5-[2...